Personalized Natural Killer Cell Therapy

Personalized NK Cell Therapy After Chemotherapy and Cord Blood Transplant in Treating Patients With Myelodysplastic Syndrome, Leukemia, Lymphoma or Multiple Myeloma

What's the purpose of the trial?

This phase II clinical trial studies how well personalized natural killer (NK) cell therapy works after chemotherapy and umbilical cord blood transplant in treating patients with myelodysplastic syndrome, leukemia, lymphoma or multiple myeloma.

Trial status

Accepting patients

Phase
Phase 2
Enrollment
100
Last Updated
2 days ago
Patient Screener

Participating Centers

There is one center participating in this trial. Enter a location below to view the distance.

Experimental Treatments

Learn more about the experimental treatments being evaluated in this clinical trial.

  • Antithymocyte Globulin (ATG) is an antibody preparation made from rabbits or horses immune cells altered with human thymocytes. ATG is used to prevent or treat acute cellular rejection after solid organ transplantation and as a therapy for certain other blood disorders.
  • Busulfan is a chemotherapy cancer medication that interferes with the growth and spread of cancer cells in the body, and may be used in the treatment of many different cancers.
  • Clofarabine is a chemotherapy medication that may be used in the treatment of many different cancers.
  • Cyclophosphamide is a chemotherapy agent used in the treatment of cancer.
  • Fludarabine is a chemotherapy medication that may be used in the treatment of many different cancers.
  • Natural Killer (NK) Cells (Allogeneic) are cells already found in the body that are being modified and tested in cancer patients to try to help reduce transplant cell production time and reduce graft versus host disease. 
  • Radiation therapy uses high doses of radiation to help target and kill many different kinds of cancer throughout the body.
  • Rituximab is an anti-CD20 monoclonal antibody currently approved for use in B-Cell Non-Hodgkins Lymphoma, Chronic Lymphocytic Leukemia, and several autoimmune conditions.

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print a patient-friendly report to share with your patient.

(888) 850-0650

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.